Zincast Tablet contains Levocetirizine 5 mg and Montelukast 10 mg, combining an antihistamine and a leukotriene receptor antagonist to effectively manage allergic conditions. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, rhinorrhea, nasal itching, and urticaria. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors, preventing bronchoconstriction, inflammation, and mucus production associated with allergic rhinitis and asthma. This combination is indicated for the treatment of allergic rhinitis, chronic idiopathic urticaria, and as adjunctive therapy in asthma management to improve symptom control and reduce exacerbations. Zincast Tablet offers the advantage of targeting multiple inflammatory pathways, providing comprehensive relief from allergic symptoms. It is generally well tolerated, with a low incidence of adverse effects such as headache, fatigue, and gastrointestinal disturbances. The recommended dosage should be followed as prescribed by a healthcare professional. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in individuals with hypersensitivity to any component. Zincast Tablet should be used under medical supervision to ensure optimal therapeutic outcomes and safety.